IBRXBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

ImmunityBio

$9.43
+2.50% today · $9.72B mkt cap
Forensic verdict

Narrative Risk

Elevated structural risk. The narrative shows pressure that has not yet resolved into a clean trap.

71%
Signal conviction
Hit rate: 82% · 11 trades
Fair-value divergence
+207.3%
Far above fair value · fair value $2.96
Verification match
90/100
Claims vs. SEC filings
Epistemic drift
0/100
Story vs. disclosures
Source authority
65/100
Outlet credibility
Coordination
Organic spread
Cross-source timing & phrasing — score 0.
Price-impact probability
WKS 0
Bearish directional energy · ACS 68
Trading footprint
Moderate concern
Tape anomaly read — distinct from the narrative signal.
Narrative decay
4d half-life
Clear Path regime
Today’s strategy signals
All strategies →
No named-playbook signal fired for IBRX today. These are short-term technical screens — most names don’t trigger on a given day.
Tracked price · last 90 sessions
Interactive Signal Lab →
Narrative under audit
“ImmunityBio (IBRX), with its ANKTIVA immuno-oncology therapy and Cancer BioShield platform, is positioned as a significant emerging competitor to established pharmaceutical companies like Eli Lilly and Novo Nordisk in the oncology market.”
Recent narratives tracked
01

ImmunityBio (IBRX), with its ANKTIVA immuno-oncology therapy and Cancer BioShield platform, is positioned as a significant emerging competitor to established pharmaceutical companies like Eli Lilly and Novo Nordisk in the oncology market.

02

Immunitybio Inc.'s financial performance, including its revenue and earnings per share, is available for review, reflecting the company's recent operational results.

03

Immunitybio Inc.'s financial performance is being tracked, with its latest financial metrics available for review.

Go deeper on ImmunityBio
Open the full interactive dossier — narrative clusters, price-impact dots, and the live Signal Lab.
Open full dossier

Forensic research, not investment advice. Scores reflect how the narrative holds up against the filings as of 2026-07-02.